These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 17337887)

  • 1. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.
    Diener HC; Sacco RL; Yusuf S; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; VanderMaelen C; Voigt T; Weber M; Yoon BW;
    Lancet Neurol; 2008 Oct; 7(10):875-84. PubMed ID: 18757238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    Sacco RL; Diener HC; Yusuf S; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; Vandermaelen C; Voigt T; Weber M; Yoon BW;
    N Engl J Med; 2008 Sep; 359(12):1238-51. PubMed ID: 18753638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PRoFESS trial: future impact on secondary stroke prevention.
    Diener HC
    Expert Rev Neurother; 2007 Sep; 7(9):1085-91. PubMed ID: 17868007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
    Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inhibition of platelet aggregation and angiotensin II-receptor blockade following TIA; the unexpected results of the Prevention Regimen For Effectively Avoiding Second Strokes (PROFESS) trial].
    Kappelle LJ
    Ned Tijdschr Geneeskd; 2008 Aug; 152(35):1907-10. PubMed ID: 18808078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Weber R; Weimar C; Wanke I; Möller-Hartmann C; Gizewski ER; Blatchford J; Hermansson K; Demchuk AM; Forsting M; Sacco RL; Saver JL; Warach S; Diener HC; Diehl A;
    Stroke; 2012 Feb; 43(2):350-5. PubMed ID: 22267825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study.
    Weimar C; Cotton D; Sha N; Sacco RL; Bath PM; Weber R; Diener HC
    Cerebrovasc Dis; 2013; 35(6):538-43. PubMed ID: 23816610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
    Malloy RJ; Kanaan AO; Silva MA; Donovan JL
    Clin Ther; 2013 Oct; 35(10):1490-1500.e7. PubMed ID: 24139421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antithrombotic therapy after cerebral ischemia].
    Schellinger PD; Orberk E; Hacke W
    Fortschr Neurol Psychiatr; 1997 Sep; 65(9):425-34. PubMed ID: 9417427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
    Bath PM; Cotton D; Martin RH; Palesch Y; Yusuf S; Sacco R; Diener HC; Estol C; Roberts R;
    Stroke; 2010 Apr; 41(4):732-8. PubMed ID: 20181679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
    Jamieson DG; Parekh A; Ezekowitz MD
    J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.
    Diener HC
    J Hypertens Suppl; 2009 Jul; 27(5):S31-6. PubMed ID: 19587553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet Therapy After Noncardioembolic Stroke.
    Greving JP; Diener HC; Reitsma JB; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Algra A
    Stroke; 2019 Jul; 50(7):1812-1818. PubMed ID: 31177983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract]   [Full Text] [Related]  

  • 18. What is better antiplatelet agent to prevent recurrent stroke?
    Wadiwala MF; Kamal AK
    J Pak Med Assoc; 2012 Sep; 62(9):976-7. PubMed ID: 23139991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention.
    Chaturvedi S
    Clin Ther; 2008 Jul; 30(7):1196-205. PubMed ID: 18691981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
    Hilkens NA; Algra A; Diener HC; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Greving JP
    Stroke; 2021 Oct; 52(10):3258-3265. PubMed ID: 34304604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.